Tag: cpt 81225

Medicare Ends Coverage for Some Pharmacogenomic Testing

By Mary Van Doren, from the Volume XXII NO. 9 - June 22, 2015 issue

CEO SUMMARY: Medicare’s decision to cease covering many pharmacogenomic tests puts as many as 19 million Americans who have genetic variations affecting their response to medications at risk. These medications are commonly prescribed for patients with cardiovascular disease, pain, depression, anxiety, and cancer. Meanwhile, medical centers such as Mayo Clinic are conducting clinical studies to collect evidence that appropriate use of pharmacogenomic tests can improve patient outcomes while also reducing the cost of care.

View Article

Medicare Ends Coverage for Genetic Drug-Sensitivity Tests

By Joseph Burns, from the Volume XXII NO. 9 - June 22, 2015 issue

View Article

Report Shows Price Drop for Most Molecular Tests

By Joseph Burns, from the Volume XX No. 9 - July 8, 2013 issue

CEO SUMMARY: In recent weeks, labs are reporting that Medicare contractors have begun to issue payments for molecular test claims filed—but unpaid—since January 1, 2013. A newly-issued analysis of this situation by Quorum Consulting indicates that, for many molecular assays, Medicare contractors are now paying less than they paid for the same tests last year.

View Article

Volume XXVI No. 5 – April 8, 2019

IT'S A FIRST FOR THE CLINICAL LAB INDUSTRY - and American industry as a whole. This issue exclusively reveals that after two years of testing, a lab has achieved the first revenue-generating flight of an unmanned drone in the U.S. Now, the lab's transport of supplies and specimens can safely bypass traffic regularly. Remarkably, the project has involved the cooperation of UPS and both the FAA and state regulators. Also, TDR reports that another government initiative, the National Correct Coding Initiative, has apparently gone awry. Labs could be harmed if they submit claims incorrectly based on the NCCI.

See the full table of contents

Tag: cpt 81225

Enter Your Login Credentials